Related Experiment Videos
Activated protein C in severe sepsis.
1St George's Hospital, London, UK.
Intensive & Critical Care Nursing
|March 1, 2002
Summary
A large trial demonstrated that recombinant activated protein C significantly lowered mortality rates in patients with severe sepsis. This marks a major breakthrough in sepsis treatment, offering new hope beyond antibiotics.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Infectious Diseases
Background:
- Severe sepsis presents a significant global health challenge with high mortality rates.
- Current treatment options for severe sepsis are limited, with antibiotics being the primary therapy for decades.
Purpose of the Study:
- To evaluate the efficacy of recombinant activated protein C in reducing mortality in patients with severe sepsis.
- To assess the impact of recombinant activated protein C as a novel therapeutic agent for severe sepsis.
Main Methods:
- A large-scale clinical trial was conducted.
- The study involved patients diagnosed with severe sepsis.
Main Results:
- Recombinant activated protein C demonstrated a significant reduction in mortality among patients with severe sepsis.
- This finding represents a substantial advancement in the pharmacotherapy of sepsis.
Conclusions:
- Recombinant activated protein C is a promising new treatment for severe sepsis.
- This therapy offers a significant improvement over existing treatment paradigms for sepsis.